Status:
COMPLETED
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
Lead Sponsor:
MediGene
Conditions:
Adenocarcinoma
Metastasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The intention of this trial is to evaluate safety and efficacy of a combination treatment of EndoTAG-1 with Gemcitabine versus Gemcitabine monotherapy.
Eligibility Criteria
Inclusion
- Inoperable adenocarcinoma of the pancreas
- Histologic or cytologic confirmation
- At least 18 years of age
Exclusion
- Any chemotherapeutical treatment for pancreatic adenocarcinoma before enrollment
- Major surgery within 4 weeks prior to enrollment
- Major cardiovascular disease
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
212 Patients enrolled
Trial Details
Trial ID
NCT00377936
Start Date
September 1 2005
End Date
October 1 2008
Last Update
November 14 2008
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Prague, Czechia
2
Budapest, Hungary
3
Kiev, Ukraine